A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis
NCT03759197 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 206
Last updated 2020-02-25
Summary
This Phase 3 study (Study 305) has been designed to determine and compare the efficacy and safety of 188-0551 Spray and Vehicle Spray applied twice daily for up to four weeks in subjects with plaque psoriasis. Subjects will be instructed to apply the test article (188-0551 Spray or Vehicle Spray) to all psoriasis plaques within the designated Treatment Area twice daily for four weeks (Study Day 29), unless the investigator verifies the subject's psoriasis has cleared at Day 15, then test article application will be for 2 weeks (Study Day 15).
Conditions
Interventions
- DRUG
-
188-0551 Spray
Topical Spray containing active drug
- DRUG
-
Vehicle Spray
Topical Spray containing no active drug
Sponsors & Collaborators
-
Therapeutics, Inc.
lead INDUSTRY
Principal Investigators
-
Tony Andrasfay · Therapeutics, Inc.
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-11-26
- Primary Completion
- 2019-08-27
- Completion
- 2019-08-27
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03611751 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
NCT01873677 ·Status: COMPLETED ·Phase: PHASE3
-
GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis
NCT03202004 ·Status: WITHDRAWN ·Phase: PHASE3
-
Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis
NCT00539929 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
NCT00396422 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
NCT01729754 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
NCT01878461 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
NCT01010542 ·Status: TERMINATED ·Phase: PHASE1
-
Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis
NCT03463187 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
NCT00399906 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
NCT03145948 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis
NCT03960450 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
NCT00805480 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies
NCT00338143 ·Status: COMPLETED ·Phase: PHASE3
-
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
NCT03721172 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients
NCT01301157 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
NCT03624127 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00235820 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
NCT03589885 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
NCT00770965 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
NCT01474512 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00237887 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
NCT03706209 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
NCT06875934 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies
NCT00689481 ·Status: COMPLETED ·Phase: PHASE3